Vaginal and oral probiotics effect in the prevention of preterm delivery in patients visiting Kamali Hospital, Karaj, Iran in 2020

Elahe Solgi, Bahareh Tavakoli-Far, Bita Badehnoosh, Armin Khavandegar, Mahmood Bakhtiyari

**Article Info**

**Keywords:**
Oral probiotics
Preterm birth
Premature delivery
Vaginal probiotics

**Abstract**

Introduction: The prevalence of preterm labor (PTL) is growing, and annually one in ten babies is born prematurely. Various studies have examined the effect of oral or vaginal probiotics on the prevention of preterm labor, which has yielded contrasting results. This study aimed to compare the impact of vaginal and oral probiotics on the prevention of preterm delivery.

Methods: This clinical trial was performed among 185 pregnant women with a gestational age greater than or equal to 25 weeks visiting Kamali Hospital, Karaj, Iran in 2020. The participants were divided into three groups; intervention group 1 receiving Oral probiotic pill once a day until 37 weeks of pregnancy, intervention group 2 receiving probiotic vaginal suppository once a day until 37 weeks of pregnancy, and control group not receiving any intervention. Patients were then followed up until the end of pregnancy.

Results: Demographic characteristics and gestational age at the time of intervention were not significantly different among the three groups. Overall, 26.7% in the control group, 30% in intervention group 1%, and 22.5% in intervention group 2 had deliveries less than 37 weeks. There was no significant difference in the frequency of preterm labor and the duration of pregnancy among the groups (all p > 0.05).

Conclusion: Probiotics use does not increase the rate of preterm delivery or reduce the duration of pregnancy, but the rate of preterm delivery was lower in the oral probiotic group. Further clinical studies on the impact of probiotics on PTL can yield valuable results.

Introduction

Preterm labor (PTL) is a medical condition defined by cervical change and regular uterine contractions happening before 37 weeks of gestation. Annually, PTL leads to 15 million premature births, nearly one million neonates die and many more suffer from lifelong disabilities [1]. Premature neonates are at risk for increased gastrointestinal and respiratory complications and long-term neuro-developmental disabilities. Therefore, it is vital to identify the best treatment method to prevent PTL, and in turn, neonatal mortality and morbidity [2].

Some risk factors can predict the onset of preterm labor with a sensitivity of 25%. These factors include low maternal weight, a previous history of preterm labor, vaginal bleeding, multiple gestations, and genitourinary bacterial infections. Vaginal infections and vaginosis either directly or indirectly through premature rupture of the membranes play a critical role in the occurrence of preterm labor [3].

Bacterial vaginosis is the most common cause of vaginitis during reproductive years and in pregnancy. Bacterial vaginosis is a polymicrobial dysbiosis disease, described by a change in the endogenous vaginal microflora with a reduced amount of lactobacilli. Reduced
vaginal lactobacilli increase the pH of the vagina and provide an opportunity for anaerobic growth [4]. The use of antibiotics is the first line of treatment for vaginitis in pregnant and non-pregnant women, and in this treatment the use of antibiotics, such as metronidazole and clindamycin, is common. Of course, antibiotic resistance in pathogenic bacteria is one of the major concerns of the medical community, and the only way to prevent the exacerbation of this problem is to reduce the use of antibiotics [5]. Probiotics can be a safe and effective alternative to antibiotics in restoring the imbalance of vaginal microbiota in bacterial vaginitis [6].

Prebiotics are indigestible food components such as oligosaccharides, resistant starch, and dietary fiber. They confer health benefits by producing important changes in the arrangement of the gut microflora by amplifying the numbers of potentially health-promoting bacteria and decreasing potentially damaging species [7]. Probiotics are live microorganisms that, if administered in suitable amounts, confer health benefits on the host [8]. Probiotics can prevent PTL through the improvement of anti-inflammatory cytokines and decreasing the pH to make the vaginal environment friendlier to beneficial bacteria. Also, a lower pH leads to the production of lactic acid, hydrogen peroxide, and antimicrobial agents, such as lactosin and bacitracin, and inhibits pathogenic bacteria in the vagina [6]. However, this is still largely hypothetical and probiotics may also be harmful to the baby, which warrants further study. Therefore, this study aimed to compare the effects of vaginal and oral probiotics in the prevention of PTL in patients visiting Kamal Hospital in 2020.

Materials and methods

Patients

This retrospective cohort study was conducted among 185 pregnant women visiting Kamal Hospital, Alborz, Iran for routine pregnancy care. Pregnant women with a gestational age greater than or equal to 25 weeks who met the inclusion criteria were enrolled in the study. The inclusion criteria comprised gestational age greater than or equal to 25 weeks, healthy amniotic sac, no probiotics consumption, no intrauterine infection, no abnormalities in the mother including pyelonephritis, preeclampsia, chronic hypertension, diabetes, oligohydramnios, polyhydramnios, placental abortion, hepatic impairment, unclear fetal heart rate pattern in monitoring, or cervical shortening, and maternal willingness to participate in the study. The exclusion criteria were the mother’s unwillingness to continue working, cervical length less than 3 cm, the presence of labor signs, and labor pains. The sample size was considered to be 185 people with 95% confidence, 0.05 error, and a low effect size of 0.15%. Before conducting the study, the study procedure and objectives were fully explained to the participants. Then, the patients signed a written consent to participate in the study. The sampling process was performed by the convenience sampling method and continued until reaching the required sample size.

Study protocol

The participants were divided into three groups as follows. Intervention group I (n = 40) received one oral probiotic capsule (Lactofen contains Lac acidophilus, Lac Plantarum, Lac frementum, and Lac gaseri) daily for 37 weeks of pregnancy. Intervention group II (n = 40) received one vaginal probiotic capsule (Lactovag contains Lac Plantarum, Lac acidophilus, Lac rhamnosus, Lac gaseri) daily for 37 weeks of gestation, and the control group (n = 105) received no interventions.

The method of consumption was explained to the participants. The participants received routine prenatal care during the study, and the researcher at each visit asked the participants about how they used the medication. In case of maternal or fetal problems, treatment and necessary medical instructions were provided by the patient’s specialist physician.

The patients were followed up until the end of pregnancy, then a checklist containing demographic characteristics (i.e., age, body mass index [BMI], smoking, etc.), type of delivery, gestational age at delivery via first-trimester ultrasound, delivery information, and any history of abortion and intrauterine fetal death (IUFD), COVID-19 infection, periodontal diseases, fertility aid use, cervical surgery, uterine malformations, asymptomatic bacteriuria, and genital infection were recorded for each participant.

Statistical analysis

Descriptive data are summarized as mean, standard deviation, and/or percentage. The normality of the data was checked before data analysis using the One-Sample Kolmogorov-Smirnov test. Descriptive statistics, such as ANOVA and Chi-square test, were used to analyze the data. All the analyses were performed using SPSS (version 20). A P-value of less than 0.05 was considered statistically significant.

Ethical considerations

The study protocol was reviewed and approved by the Ethics committee of Alborz University of Medical Sciences, Karaj, Iran (Number: IR. ABZUMS.REC.1399.222), and the study was registered at the Iranian Registry for Clinical Trials (code: IRTC20201024049128N2). Written informed consent was obtained from all the participants. Before performing the study, the eligible women were informed of the study objectives and ensured the confidentiality of the data.

Results

A total of 185 people were included in this study. The characteristics of participants in this study are shown in Table 1. The statistical analyses revealed that the three groups were not significantly different in age (P = 0.62), BMI (P = 0.85), and gravidity (P = 0.69).

Most of the women in the three groups were housewives (control group 84.7%, vaginal probiotic and oral probiotic group 92.5%). In terms of education, the majority of the women in the control group (49.5%)

| Table 1 Characteristics of the participants. |
|---------------|-----------------|---------------|---------------|---------------|
| Variable       | Control group (n = 105) | Vaginal probiotic group (n = 40) | Oral probiotic group (n = 40) | P-value |
| Age (yr)        | 31.38 ± 7.68     | 30.01 ± 6.77   | 30.80 ± 6.63   | 0.62      |
| BMI (kg/m²)     | 27.88 ± 9.49     | 28.50 ± 5.99   | 28.12 ± 5.31   | 0.85      |
| Gravidity (%)   | 2.22 ± 1.32      | 1.20 ± 2.02    | 1.17 ± 2.17    | 0.69      |
| Employment status | Housewife   | Employed     | Employed     |          |
|                 | 89 (84.7%)       | 37 (92.5%)    | 37 (92.5%)    | 0.22      |
|                 | Employed         | 16 (15.3%)    | 3 (7.5%)      |          |
| Education n (%) | Primary School   | High School   | Associate Degree |          |
|                 | 9 (8.6%)         | 13 (12.4%)    | 8 (7.6%)      | 21 (52.5%) |
|                 | 3 (7.5%)         | 3 (7.5%)      | 2 (5%)        |          |
| Smoking (%)     | 6 (5.7%)         | 2 (5%)        | 1 (2.5%)      |          |
| Depression (%)  | 7 (6.7%)         | 4 (10%)       | 4 (10%)       | 0.71      |
| COVID-19 infection (%) | 52 (49.5%) | 15 (37.5%) | 14 (35.9%) | 0.19     |
| Periodontal disease (%) | 6 (5.8%) | 3 (7.5%) | 2 (5%) | 0.88     |
| Preterm delivery history (%) | 9 (8.6%) | 3 (7.5%) | 3 (7.5%) | 0.96     |
| History of IUFD (%) | 12 (11.4%) | 3 (7.5%) | 3 (7.5%) | 0.67     |

* mean ± SD; BMI: Body mass index; IUFD: Fetal intrauterine death.

The patients were followed up until the end of pregnancy, then a checklist containing demographic characteristics (i.e., age, body mass index [BMI], smoking, etc.), type of delivery, gestational age at delivery via first-trimester ultrasound, delivery information, and any history of abortion and intrauterine fetal death (IUFD), COVId-19 infection, periodontal diseases, fertility aid use, cervical surgery, uterine malformations, asymptomatic bacteriuria, and genital infection were recorded for each participant.
COVID-19 infection is also among the factors that have recently been smoking, depression, and COVID-19 infection. 

The prevalence rates of periodontal diseases in the control, vaginal probiotic, and oral probiotic groups were 5.8 %, 7.5 %, and 5 %, respectively, and 8.1 % of the women had a history of preterm delivery and 9.7 % of them had IUFD. The statistical analyses exhibited that the three groups did not differ significantly in terms of job (P = 0.22), level of education (P = 0.22), smoking status (P = 0.27), history of depression (P = 0.22), history of COVID-19 (P = 0.19), periodontal diseases (P = 0.88), history of preterm delivery (P = 0.96), and IUFD (P = 0.67). These results show that the distribution of these variables was the same among the three groups.

The mean gestational age at the time of intervention (P = 0.82) and gestational age at delivery (P = 0.64) was not significantly different among the three study groups (Table 2). These results show the distribution of these variables was the same among the three groups. However, gestational age was higher in the oral probiotic group than in the other two groups, although this difference was not significant.

In addition, 26.7 % (n = 28) in the control group, 30 % (n = 12) in the vaginal probiotic group, and 22.5 % (n = 9) in the oral probiotic group had less than 37 weeks of gestation. No significant differences were observed among the three groups based on the Chi-square test (P = 0.74). However, the rate of preterm delivery was lower in the oral probiotic group, although it was not significantly different.

### Discussion

Preterm labor management has always been a concern for obstetricians, and selecting a suitable treatment is of particular importance due to the short duration of treatment in PTL. The current study investigated the effectiveness of vaginal probiotics and oral probiotics in the prevention of PTL. The results showed that probiotic use did not elevate the rate of preterm delivery or duration of pregnancy compared with placebo. However, the rate of preterm delivery was lower in the oral probiotic group, although this difference was not significant.

Numerous risk factors for PTL have been reported. Important risk factors for PTL, such as age, race, education, and bacterial vaginosis, are related to low socio-economic status. The most important risk factor for PTL is the history of preterm delivery, which leads to a three-fold increase in the risk of a subsequent preterm delivery and is probably related to underlying risk factors [9]. Maternal age is one of the most important factors, such that the risk of PTL is significantly higher in both older and younger ages [10,11]. Other known risk factors include cervical insufficiency, abortion and IUFD in previous pregnancies [12-16], maternal stress and depression [17], BMI [18,19], periodontal disease [20], and smoking [21], uterine bleeding, and immune system disorders. COVID-19 infection is also among the factors that have recently been linked to preterm labor. In the present study, the results of the analyses showed that the three groups were not significantly different in terms of age, BMI, history of preterm labor, IUFD in previous pregnancies, smoking, depression, and COVID-19 infection.

### Table 2

| Variable                      | Control group (n = 105) | Vaginal probiotic group (n = 40) | Oral probiotic group (n = 40) | P-value |
|-------------------------------|-------------------------|---------------------------------|-------------------------------|---------|
| Gestational age at time of intervention | 30.11 ± 3.41            | 29.75 ± 5.33                   | 29.95 ± 4.66                 | 0.82    |
| Gestational age at delivery   | 38.06 ± 2.64            | 37.82 ± 2.87                   | 38.37 ± 2.24                 | 0.64    |

Mean ± SD; ANOVA test.

Among PTL risk factors, bacterial vaginosis (BV) as an infectious disorder is of great significance. Bacterial vaginosis occurs in 15–20 % of normal pregnant women in developed countries [22], and this amount almost doubles in high-risk women [23]. Evidence suggests that BV is one of the causes of poor pregnancy outcomes, especially preterm labor, sepsis, necrotizing enterocolitis, intraventricular and intraventricular hemorrhage, neonatal lung injury, and intraventricular leukomalacia, and cerebral palsy [24]. Achdiat et al. reported that women with BV and abnormal vaginal flora are at risk for preterm delivery and late miscarriage [25]. Similar observations were reported in other studies that showed a significant association between abnormal genital flora and adverse pregnancy outcomes [26]. Yarlagadda et al. showed that detecting abnormal flora early in pregnancy indicates a high risk for PTL [27]. Another study demonstrated two types of abnormal vaginal flora, one predominantly BV, and the other aerobic microorganisms, such as Klebsiella and Escherichia coli, in women with PTL [24]. This proves a significant link between abnormal vaginal flora and its associated complications in pregnancy (preterm labor); thus, new treatment strategies should aim to restore the abnormal vaginal flora to prevent PTL.

The probiotics lactulose, galacto-oligosaccharide (GOS), and fructo-oligosaccharides (FOS) have been displayed to provide substrates for the development of lactobacilli and bifidobacterial, proposing that they could contribute to the helpful effects of probiotics [28]. A meta-analysis of clinical trials on the impact of probiotics established that probiotics are both safe and effective for the treatment and prevention of many infectious and inflammatory diseases [29]. The use of antibiotics for BV treatment in pregnant and non-pregnant women remains the method of choice, which is still too frequently ineffective [30]. Some studies reported that lactobacilli can decrease BV recurrence and grow lactobacilli abundance in the vagina of non-pregnant and pregnant women [31,32]. The results of this study showed that probiotic use did not increase the rate of preterm delivery or duration of pregnancy compared with placebo. Nevertheless, the rate of preterm delivery was lower in the oral probiotic group. Some studies have examined the effect of probiotics on the prevention of pregnancy complications such as preterm delivery. However, due to differences in the type of prescription probiotics and the study population, these studies are not homogeneous. A retrospective study of pregnant women who took probiotics containing Streptococcus faecalis, Clostridium butyricum, and Bacillus mesentericus to prevent bacterial vaginosis showed that probiotics significantly reduced preterm labor before 32 weeks and the rate of chorioamnionitis in these patients [33]. Another study reported that the mean gestational age, duration of labor delay, and birth weight in the probiotic group were higher than in the control group [34].

Similar to the results of our study, Kopp et al. described that the use of probiotics in pregnant women 4–6 weeks before the expected delivery was not associated with gestational age at delivery, birth weight, and delivery method [35]. To the best of our knowledge, no side effects have been reported for probiotic consumption in any clinical trial.

### Limitations and suggestions

The main limitations of the current study were the small sample size which limits reliable inferences about the efficacy of the tested probiotics in preventing PTL. Therefore, it is suggested to perform further randomized clinical trials with larger sample sizes. Future clinical studies should consider the suitable probiotic strain(s), probiotic doses, duration of treatment, and route of administration. The administration of a few probiotic strains is safe for use in pregnancy and it potentially confers health benefits, one of which is lowering the risk of PTL.

### Conclusion

The results showed probiotic use did not increase the rate of preterm delivery and duration of pregnancy compared with placebo. This may be due to the limited sample size or time of administration (late
pregnancy). It is recommended that studies with larger sample sizes be performed with probiotic administration at different points in pregnancy.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

The authors would like to thank the Clinical Research Development Unit (CRDU) of Emami Ali Hospital, Alzbor University of Medical Sciences, karaj, Iran for their support, cooperation and assistance throughout the period of study.

**References**

1. Kliegman R, Gene J. Nelson textbook of pediatrics, vol. 2. Elsevier; 2019. p. 1833-6.
2. Trembath AN, Payne AH, Colaży TY, Bell EF, Walsh MC, editors. The problems of moderate preterm infants. Seminars in perinatology; 2016: Elsevier.
3. Purisch SE, Gyamfi-Bannerman C, editors. Epidemiology of preterm birth. Seminars in perinatology; 2017: Elsevier.
4. Tidbury FD, Langhart A, Weidlinger S, Stute P. Non-antibiotic treatment of bacterial vaginosis—a systematic review. Arch Gynecol Obstet 2021;303(1):37-45.
5. Sivanaruthi BS, Kesika P, Chaiyasut C. A review on anti-aging properties of probiotics. Int. J Appl Pharm 2018;10(5):23-7.
6. Jarde A, Lewis-Mikhael A-M, Moayyedi P, Stearns JC, Collins SM, Beyene J, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2018;18(1):1-14.
7. Organization W.H. FAO/WHO framework for the provision of scientific advice on food safety and nutrition: Food & Agriculture Org.; 2018.
8. Krasun-Silva L, Moreira MEI, Alves MB, Braga A, Camacho KG, Batista MRR, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2018;18(1):1-14.
9. Fuchs F, Monet B, Ducruet T, Chaillet N, Audibert F. Effect of maternal age on the risk of preterm delivery associated with bacterial vaginosis: preliminary results. Trials 2011;12(1):1-11.
10. Bodean O, Munteanu O, Cirstoiu C, Secara D, Cirstoiu M. Probiotics—a helpful additional therapy for bacterial vaginosis. J Med Life 2013;6(4):434.
11. Staneva A, Bogossian F, Pritchard M, Wittkowski A. The effects of maternal height and the risk of bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG: Int J Obstet Gynaecol 2009;116(10):1315-24.
12. Han Y, Ren Q-l. Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis? J Obstet Gynaecol Can 2012;34(8):721-46.
13. Basavarajappa H, Sonu K, Prabha R. Mechanistic insights into the action of probiotics against bacterial vaginosis and its mediated preterm birth: an overview. Microb Pathog 2020;141:104629.
14. Goldenberg RL, Iams JD, Mercer BM, Meis P, Moawad A, Das A, et al., editors. What have we learned about the predictors of preterm birth. Seminars in Perinatology; 2003: Elsevier.
15. Krauss-Silva L, Moreira MEL, Alves MB, Braga A, Camacho KG, Batista MRR, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2018;18(1):1-14.
16. Homayouni A, Bastani P, Ziyadi S, Mohammad-Alizadeh-Chamandabi S, Ghalbaf M, Mortazavian AM, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis 2014;18(1):79-86.
17. Han Y, Ren Q-L. Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis. Curr Opin Pharmacol 2021;61:83-90.
18. Daskalakis GJ, Karabekas AK. Vaginal probiotic administration in the management of preterm premature rupture of membranes. Fetal Diagn Ther 2017; 42(2):92-8.
19. Bhakta V, Aslam S, AliJaghawani A. Bacterial vaginosis in pregnancy: prevalence and outcomes in a tertiary care hospital. Afr J Reprod Health 2021;25(1):49-55.
20. Yarlagadda S, Sajana G, Narra PJ. Association of vaginal infections in preterm labour. Int J Reprod, Contracept Obstet Gynecol 2018;7(6):2174-80.
21. Song SK, Beck BR, Kim D, Park J, Kim J, Kim HD, et al. Prebiotics as immunomodulators in aquaculture: a review. Fish Shellfish Immunol 2014;40(1):40-8.
22. Averbach SH, Seidman D, Steinauer J, Darney P. Re: Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2017;216(1):87.
23. Han Z, Lutoviv, Mulla S, McDonald SD, Group KS. Maternal height and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. J Obstet Gynaecol Can 2012;34(8):721-46.
24. Han Y, Ren Q-L. Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis? J Obstet Gynaecol Can 2012;34(8):721-46.
25. Colicchia LC, Simhan HN. Optimizing subsequent pregnancy outcomes for women with a prior preterm birth. Am J Perinatol 2016;33(3):267-75.
26. Ke L, Lin W, Liu Y, Ou W, Lin Z. Association of induced abortion with preterm birth risk in first-time mothers. Sci Rep 2018;8(1):1-6.
27. Frolich SH, Seidman D, Steinauer, J, Darney P. Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and meta-analysis. Am J Obstet Gynecol 2017;216(1):87.
28. Han Z, Lutoviv, Mulla S, McDonald SD, Group KS. Maternal height and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. J Obstet Gynaecol Can 2012;34(8):721-46.